Assetmark Inc. Buys 1,076 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Assetmark Inc. raised its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 5.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,382 shares of the company’s stock after purchasing an additional 1,076 shares during the quarter. Assetmark Inc.’s holdings in Inari Medical were worth $799,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of NARI. GAMMA Investing LLC increased its stake in shares of Inari Medical by 164.7% in the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after buying an additional 438 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after buying an additional 435 shares during the period. Covestor Ltd increased its stake in shares of Inari Medical by 30.2% in the first quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after buying an additional 376 shares during the period. Benjamin F. Edwards & Company Inc. increased its stake in shares of Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after buying an additional 522 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Inari Medical in the second quarter worth $104,000. 90.98% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the sale, the chief executive officer now directly owns 445,310 shares in the company, valued at $22,265,500. This trade represents a 0.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the transaction, the director now directly owns 601,233 shares of the company’s stock, valued at approximately $27,067,509.66. The trade was a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 126,000 shares of company stock worth $5,921,390 over the last three months. 10.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on NARI shares. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Truist Financial upped their target price on shares of Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research report on Tuesday, October 29th. Leerink Partners assumed coverage on shares of Inari Medical in a research report on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 target price on the stock. Canaccord Genuity Group upped their target price on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. Finally, Wells Fargo & Company reduced their target price on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Six analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Inari Medical has an average rating of “Hold” and a consensus price target of $58.89.

Inari Medical Price Performance

Inari Medical stock opened at $50.56 on Friday. The stock’s 50 day moving average price is $45.19 and its 200 day moving average price is $46.94. The company has a market cap of $2.96 billion, a PE ratio of -37.45 and a beta of 0.96. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $67.13.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.